Business
Aytu BioScience Announces Acceptance of Results of Two Natesto Clinical Studies for Presentation at American Urological Association Annual Scientific Program
ENGLEWOOD, CO / ACCESSWIRE / February 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"ENGLEWOOD, CO / ACCESSWIRE / February 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced the acceptance of scientific abstracts reporting the findings from two Natesto® clinical studies for presentation at the American Urological Association's AUA2020 Scientific Program. The AUA2020 meeting will be held May 15th - 18th in Washington, DC.Natesto Spermatogenesis StudyThe data readout from the Natesto Spermatogenesis Study has been accepted as a Podium Session and will be presented by lead author Thomas Masterson, MD, Urology Fellow in the Department of Urology at the University of Miami School of Medicine. The Natesto Spermatogenesis Study has been conducted under the supervision of principal investigator Ranjith Ramasamy, MD, Associate Professor and Director of Reproductive Urology, Department of Urology, University of Miami School of Medicine.Presentation Details:Presenting Author: Thomas Masterson, MD, Fellow, Department of Urology, University of Miami School of MedicineAbstract Title: The effect of Natesto on spermatogenesis, reproductive hormones, and hypogonadal symptoms. A phase IV study.Abstract Number: 20-78Hypogonadal Men Switching from Clomiphene Citrate to Natesto The results of a retrospective analysis studying hypogonadal men who converted from clomiphene citrate to Natesto will be presented at a Moderated Poster Session. The study has been conducted under the supervision of principal investigator Parviz Kavoussi, MD, FACS. Dr. Kavoussi is a Reproductive Urologist at Austin Fertility & Reproductive Medicine/Westlake IVF. He is also Adjunct Assistant Professor, Department of Urology, at the University of Texas Health Sciences Center at San Antonio, as well as Adjunct Assistant Professor at the University of Texas at Austin.Presentation Details:Presenting Author: Parviz Kavoussi, MD, Reproductive Urologist, Austin Fertility & Reproductive Medicine/Westlake IVFAbstract Title: Converting men from clomiphene citrate to Natesto for hypogonadism improves libido, maintains semen parameters, and reduces estradiol.Abstract ID: 20-6651Selection of the abstracts for publication in the press program does not imply endorsement of Natesto by the American Urological Association.About Aytu BioScience, Inc.A...